Advancement Of Gene Therapy in Blood Diseases Treatment Based On CRISPR/Cas System
DOI:
https://doi.org/10.54097/ehdyyb80Keywords:
Blood Diseases; CRISPR/Cas system; gene therapy.Abstract
Blood-related diseases are characterized as physiological disorders that affect the blood’s functions, affecting tens of millions of people’s lives every year. Serious blood disorders can be life threatening and bring patients both great physical and mental pain. Gene therapy has the potential to significantly intervene in disease from the standpoint of genetic material, resulting in a more beneficial therapeutic outcome. CRISPR/Cas system, as the third gene-editing technology, has become a powerful tool for gene editing. This review provided a brief summary of the current advancements, together with advantages, challenges of CRISPR/Cas system, and discussed future prospects of utilizing CRISPR/Cas system for genetic therapy in blood diseases.
Downloads
References
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., ... & Yu, T. (2023). CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy, 8(1), 36.
Martyn, G. E., Wienert, B., Yang, L., Shah, M., Norton, L. J., Burdach, J., ... & Crossley, M. (2018). Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nature genetics, 50(4), 498-503.
Humbert, O., Radtke, S., Samuelson, C., Carrillo, R. R., Perez, A. M., Reddy, S. S., ... & Kiem, H. P. (2019). Therapeutically relevant engraftment of a CRISPR-Cas9–edited HSC-enriched population with HbF reactivation in nonhuman primates. Science translational medicine, 11(503), eaaw3768.
Newby, G. A., Yen, J. S., Woodard, K. J., Mayuranathan, T., Lazzarotto, C. R., Li, Y., ... & Liu, D. R. (2021). Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature, 595(7866), 295-302.
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., ... & Corbacioglu, S. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252-260.
Hu, Y., Zhou, Y., Zhang, M., Ge, W., Li, Y., Yang, L., ... & Huang, H. (2021). CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clinical Cancer Research, 27(10), 2764-2772.
Kim, M. Y., Yu, K. R., Kenderian, S. S., Ruella, M., Chen, S., Shin, T. H., ... & Gill, S. (2018). Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell, 173(6), 1439-1453.
Chen, S. H., Hsieh, Y. Y., Tzeng, H. E., Lin, C. Y., Hsu, K. W., Chiang, Y. S., ... & Lee, C. H. (2020). ABL genomic editing sufficiently abolishes oncogenesis of human chronic myeloid leukemia cells in vitro and in vivo. Cancers, 12(6), 1399.
Vuelta, E., García-Tuñón, I., Hernández-Carabias, P., Méndez, L., & Sánchez-Martín, M. (2021). Future approaches for treating chronic myeloid leukemia: CRISPR therapy. Biology, 10(2), 118.
Bajaj, J., Hamilton, M., Shima, Y., Chambers, K., Spinler, K., Van Nostrand, E. L., ... & Reya, T. (2020). An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia. Nature cancer, 1(4), 410-422.
Quijada-Álamo, M., Hernández-Sánchez, M., Alonso-Pérez, V., Rodríguez-Vicente, A. E., García-Tuñón, I., Martín-Izquierdo, M., ... & Hernández-Rivas, J. M. (2020). CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del (11q) CLL cells to dual BCR and PARP inhibition. Leukemia, 34(6), 1599-1612.
Sharma, A., Boelens, J. J., Cancio, M., Hankins, J. S., Bhad, P., Azizy, M., ... & LaBelle, J. L. (2023). CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. New England Journal of Medicine, 389(9), 820-832.
Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., ... & Chen, H. (2019). CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. New England Journal of Medicine, 381(13), 1240-1247.
Fu, B., Liao, J., Chen, S., Li, W., Wang, Q., Hu, J., ... & Wu, Y. (2022). CRISPR–Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia. Nature Medicine, 28(8), 1573-1580.
Gidding, S.S.; Allen, N.B. Cholesterol and atherosclerotic cardiovascular disease: A lifelong problem. J. Am. Heart Assoc. 2019, 8, e012924.
Musunuru, K., Chadwick, A. C., Mizoguchi, T., Garcia, S. P., DeNizio, J. E., Reiss, C. W., ... & Kathiresan, S. (2021). In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature, 593(7859), 429-434.
Hu, Z., Wu, Y., Xiao, R., Zhao, J., Chen, Y., Wu, L., ... & Liang, D. (2023). Correction of F8 intron 1 inversion in hemophilia A patient-specific iPSCs by CRISPR/Cas9 mediated gene editing. Frontiers in Genetics, 14, 1115831.
Tao, J., Bauer, D. E., & Chiarle, R. (2023). Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing. Nature Communications, 14(1), 212.
Chien, Y., Hsiao, Y. J., Chou, S. J., Lin, T. Y., Yarmishyn, A. A., Lai, W. Y., ... & Yang, Y. P. (2022). Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: Applications, challenges, and emerging opportunities. Journal of Nanobiotechnology, 20(1), 511.
Arai, D., & Nakao, Y. (2021). Efficient biallelic knock-in in mouse embryonic stem cells by in vivo-linearization of donor and transient inhibition of DNA polymerase θ/DNA-PK. Scientific reports, 11(1), 18132.
Kim, H. K., Kim, Y., Lee, S., Min, S., Bae, J. Y., Choi, J. W., ... & Kim, H. H. (2019). SpCas9 activity prediction by DeepSpCas9, a deep learning–based model with high generalization performance. Science advances, 5(11), eaax9249.
Cheng, X., Li, Z., Shan, R., Li, Z., Wang, S., Zhao, W., ... & Li, W. (2023). Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches. Nature Communications, 14(1), 752.
Saito, M., Xu, P., Faure, G., Maguire, S., Kannan, S., Altae-Tran, H., ... & Zhang, F. (2023). Fanzor is a eukaryotic programmable RNA-guided endonuclease. Nature, 620(7974), 660-668.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
